IL7 and acute lymphoblastic leukemia: In our in vivo ALL model, both day 23-CAR groups had better efficacy than untreated mice, but the combination of dex-CAR and IL-7 no longer prolonged survival over untreated CAR T cells and IL-7 (Figures 5H and 5I).